Allogeneic hematopoietic cell transplantation for autoinflammatory disorders.

IF 1.8 4区医学 Q3 HEMATOLOGY

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI:10.1007/s12185-025-04021-0

Hirokazu Kanegane, Satoshi Miyamoto, Takahiro Kamiya, Hidenori Ohnishi, Ryuta Nishikomori, Andrew R Gennery, Takehiko Mori

引用次数: 0

Abstract

The understanding of autoinflammatory disorders, which are caused by the dysregulated activation of the innate immune system, has improved with the discovery of new diseases and the expansion of phenotypes. Inflammation can be controlled using immunosuppressive drugs, biological agents, and molecular-targeted therapies. However, some cases remain refractory to treatment, and certain patients experience side effects associated with the long-term use of corticosteroids. Recently, allogeneic hematopoietic cell transplantation (HCT) was reported to improve symptoms in refractory cases. Based on the previous reports, in this review, we discuss the potential of HCT in the treatment of autoinflammatory disorders.

查看原文本刊更多论文

同种异体造血细胞移植治疗自身炎性疾病。

自体炎性疾病是由先天免疫系统激活失调引起的，随着新疾病的发现和表型的扩大，对自体炎性疾病的理解得到了改善。炎症可以通过免疫抑制药物、生物制剂和分子靶向治疗来控制。然而，一些病例仍然难以治疗，某些患者经历与长期使用皮质类固醇相关的副作用。最近，异体造血细胞移植（HCT）被报道可以改善难治性病例的症状。基于以往的报道，在这篇综述中，我们讨论了HCT治疗自身炎症性疾病的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hematology 医学-血液学

CiteScore

3.90

自引率

4.80%

发文量

223

审稿时长

6 months

期刊介绍： The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.